亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

巴利森苷E CAS:952068-57-4

 
 
單價 面議對比
詢價 暫無
發貨 四川成都市付款后3天內
品牌 鈉鈳鋰
過期 長期有效
更新 2021-11-25 12:22
 

成都鈉鈳鋰生物科技有限公司

企業會員第5年
資料未認證
保證金未繳納
詳細說明

nkl-00219
中文名稱:巴利森苷E
中文別稱:派立辛 E;檸檬酸酯E
英文名稱:Parishin E
英文別稱:4-[(3,4-Dicarboxy-3-hydroxy-1-oxobutoxy)methyl]phenyl β-D-glucopyranoside; Parishin E
C A S號:952068-57-4
度:HPLC≥98%

式:C19H24O13
量:460.39
沸點: 784.1±60.0 °C | Condition
密度: 1.631±0.06 g/cm3 | Condition: Temp: 20 °C
: 3.10±0.28 | Condition: Most Acidic Temp: 25 °C
規格:20mg  50mg  100mg  500mg  g級等應客戶需求包裝
儲存條件: 2-8°C,避光、干燥、密封

用途: 用于鑒別、含量測定、藥理實驗、活性篩選等科研、實驗室使用;不得用于注射、食用或其他

供應商:成都鈉鈳鋰生物科技有限公司

舉報收藏 0評論 0
更多>本企業其它產品
2”-O-沒食子酰基金絲桃苷 CAS:53209-27-1 甘草酸 CAS:1405-86-3 甘草酸銨 CAS:53956-04-0 甘草查爾酮A CAS:58749-22-7 甘草查爾酮B CAS:58749-23-8 甘草查爾酮C CAS:144506-14-9 重樓皂苷II CAS:50773-42-7 重樓皂苷III CAS:19057-60-4
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |